Clinical Study
Liver Dysfunction Associated with Intravenous Methylprednisolone Pulse Therapy in Patients with Graves’ Orbitopathy
Table 1
Clinical characteristic of patients with Graves’ orbitopathy.
| | | Total | Male | Female | Male versus female | | | | | | value |
| | Age (yr) | 51.7 ± 15.5 | 55.9 ± 16.3 | 49.6 ± 11.9 | 0.012 |
| | BMI (kg/m2) | 22.5 ± 3.7 | 23.4 ± 3.8 | 22.1 ± 2.7 | 0.021 |
| | HBcAb (+) | 43 (25%) | 21 (37%) | 22 (19%) | 0.0102 |
| | HCVAb (+) | 17 (10%) | 9 (16%) | 8 (7%) | 0.0677 |
| | HBcAb (−) HCVAb (−) | 122 (70%) | 31 (54%) | 91 (77%) | — |
| | IVMP > 8 g | 118 (67%) | 40 (70%) | 78 (66%) | 0.5884 |
| | Smoking (+) | 57 (33%) | 27 (47%) | 30 (25%) | 0.0041 |
| | Alcohol (+) | 48 (27%) | 28 (49%) | 20 (17%) | 0.0001 |
| | CAS | 3.1 ± 1.7 | 3.2 ± 1.8 | 3.0 ± 1.7 | 0.8263 |
| | TRAb (%) | 29.3 ± 27.3 | 25.8 ± 26.1 | 30.8 ± 27.8 | 0.2987 |
| | hTRAb (IU/L) | 17.7 ± 44.4 | 8.10 ± 11.4 | 21.9 ± 52.2 | 0.0407 |
| | TSAb (%) | 1262 ± 1480 | 931 ± 1229 | 1404 ± 1559 | 0.0346 |
| | | | | |
Mean ± SD |
|
|
BMI, body mass index; HBcAb, anti-hepatitis B core antibody; HCVAb, anti-hepatitis C virus antibody; IVMP, intravenous injection of methylprednisolone; CAS, clinical activity score; TRAb, anti-thyrotrophin antibody; hTRAb, human TRAb; TSAb, thyroid stimulating antibody.
|
